8,630
+0.94%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jeil Pharmaceutical Co
Its shares trade on KRX under the ticker 271980.KS. It has been listed since 17 July 2017. In the fiscal year to 31 December 2025, it reported revenue of ₩567.24bn and net income of ₩23.38bn. At that date it held total assets of ₩510.57bn and shareholders' equity of ₩211.07bn.
Jeil Pharmaceutical Co., Ltd. engages in the development of pharmaceuticals. The company is headquartered in Seoul, Seoul. The company went IPO on 2017-07-17. The firm provides anti-inflammatory painkillers, anticancer drugs, gastritis drugs, antibiotics, ulcer treatments, antidepressant drugs, pollakisuria and incontinence treatments, impetigo drugs, septicemia treatments, hyperlipidemia treatments, peripheral neuropathic pain drugs, hypertension drugs and others. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 17 Jul 2017
- Employees
- 978
- Website
- jeilpharm.co.kr ↗
Leadership
Pay as last reported
- Mr. Seok Je SungCo-President, Chief Executive Officer, Director
- Mr. Sang Cheol HanCo-President, Director
- Mr. Jeong Jin KimManaging Director
- Mr. Chang Seok LeeManaging Director
- Mr. Chi Guk NohManaging Director
- Mr. Dong Su YangManaging Director
- Mr. Sang Wu HanManaging Director
- Mr. Si Beom LeeManaging Director
- Mr. Gwang Hyeon AhnAssistant Managing Director
- Ms. Su Mi KimAssistant Managing Director
- Mr. Chan Gwon LeeAssistant Managing Director
- Mr. Yeong Ho LeeAssistant Managing Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Jeil Pharmaceutical develops anti-inflammatory painkillers and anticancer drugs in the Korean market.
- The company distributes products domestically and to overseas markets including Japan and China.
- Jeil Pharmaceutical has 978 employees focused on pharmaceutical development and distribution.
Weaknesses
- Jeil Pharmaceutical's products include ulcer treatments and hyperlipidemia treatments with limited global market reach.
- The company's focus on domestic market distribution may limit international expansion opportunities.
- Jeil Pharmaceutical's product range includes peripheral neuropathic pain drugs but lacks innovative new drug development.
Opportunities
- Jeil Pharmaceutical can expand its anti-inflammatory painkiller sales in the Asian pharmaceutical market.
- The company has potential to increase overseas distribution to countries like Japan and China.
- Jeil Pharmaceutical can leverage its 978 employees to develop new pharmaceutical products for global markets.
Threats
- Jeil Pharmaceutical faces competition from established pharmaceutical companies in the Korean Health Care sector.
- The company's reliance on domestic market distribution may lead to revenue stagnation.
- Jeil Pharmaceutical's product portfolio includes hypertension drugs but lacks diversity in treatment areas.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.